Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests if esketamine causes fewer weird side effects than ketamine for ER pain

NCT ID NCT06853041

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compared two similar painkillers—esketamine and ketamine—given as low-dose injections to 74 adults with severe acute pain in the emergency department. The main goal was to see which drug caused fewer disturbing mental side effects like hallucinations or dizziness. Both drugs are alternatives to morphine and don't slow breathing, but their side effects can be unpleasant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Esketamine and ketamine (low-dose intravenous injections)
What this could lead to
If esketamine causes fewer disturbing side effects than ketamine, it could become a preferred option for rapid pain relief in emergency rooms, reducing reliance on opioids.
What could go wrong
This is a small, single-center study with only 74 participants, so results may not apply broadly. Both drugs can still cause hallucinations or dizziness, and the benefit of esketamine over ketamine may be minimal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

74 people

The number who actually took part.

Started

May 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 or over, * consulting our emergency department for a medical or traumatic pathology responsible for acute (less than 7 days old) and severe pain (greater than or equal to 6 on the Verbal Numerical Rating Scale, which has 11 levels from 0 = no pain to 10 = maximum imaginable pain). * Free and informed consent given before the start of the trial. * Patients affiliated to social security system. Exclusion Criteria: * Inability to quantify pain score ; * proven or suspected intoxication (drug or alcohol) leading to consciousness disorders (Glasgow score less than or equal to 15) ; * person under legal protection or deprived of liberty ; * pregnant or breast-feeding patients ; * known allergy to ketamine or esketamine ; * history of drug addiction or dependence ; * insufficiently controlled hyperthyroidism ; * history of cerebral of myocardial infarction ; * known severe heart failure ; * existence of intracranial hypertension, glaucoma or ocular trauma ; * unstable vital signs (systolic blood pressure \< 90 mmHg or \> 180, heart rate \< 50 per minute or \> 150, respiratory rate \< 10 per minute or \> 30) ; * chronic treatment with aminophylline, theophylline or methylergometrine ; * administration of morphine or another opioid within one hour of inclusion ; * ongoing simultaneous participation in another study that could interfere with the treatment studied or the results of statistical analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pain

Contacts and locations

Locations

  • CHU de NICE

    Nice, Alpes-maritimes, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.